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Abstract
Angiogenesis is the process of growth of new blood vessels. Tumor angiogenesis plays 
pivotal roles in tumor development, progression, and metastasis. The conventional notion 
of tumor vasculature is that new tumor blood vessels sprout from preexisting vasculature 
near the tumor; hence, tumor endothelial cells are derived from normal endothelial cells. 
However, recent evidence suggests that CD133‐positive cancer stem cells (CSCs) in glio‐
blastomas generate tumor endothelial progenitor cells, which further differentiate into 
tumor endothelial cells. This chapter offers an overview of current knowledge on the role 
of CSCs in tumor angiogenesis. Furthermore, we discuss our recent discoveries related to 
human hepatoblastoma stem cells. Future efforts to elucidate the characteristics of tumor 
angiogenesis should enable the development of effective new anti‐angiogenic therapies.
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1. Introduction
Angiogenesis is an essential process by which new blood vessels are formed. In malignan‐
cies, tumor growth and metastasis are angiogenesis dependent. It is widely accepted that 
new tumor blood vessels sprout from preexisting vasculature. Therefore, tumor endothelial 
cells are considered to be derived from normal endothelial cells. However, over the last few 
years, different processes by which tumor vascularization occurs have been documented. It 
has been shown that endothelial cells in the tumor vasculature arise from a small population 
of tumor cells known as cancer stem cells (CSCs) or tumor‐initiating cells. Since John Dick 
and others identified leukemia cells in 1994 [1], the presence of CSCs with similar properties 
to normal stem cells has been discovered. CSCs have the ability to undergo self‐renewal and 
differentiation into diverse cancer cells and are capable of becoming malignant. CD133 (or 
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Prominin1), a cell surface glycoprotein used widely as a marker for normal stem cells, is addi‐
tionally recognized as a marker for CSCs. Recent reports suggest that CD133‐positive CSCs 
in glioblastomas generate tumor endothelial progenitor cells, which further differentiate into 
tumor endothelial cells [2–4].
What is the origin of endothelial cells and pericytes lining tumor blood vessels? Can CSCs 
give rise to tumor endothelial cells? The origin of tumor endothelial cells is the main focus of 
this chapter. We will provide an overview of current studies and discuss the role of CSCs in 
tumor angiogenesis. We have investigated the relationship between tumor endothelial cells 
and CSCs in human hepatoblastoma, which is the most frequent type of malignant tumor to 
occur in the pediatric liver. Our findings are reported in this chapter.
2. Characteristics of tumor blood vessels
The field of angiogenesis research arose following a publication by Folkman in 1971. The future of 
anticancer therapy was emphasized in that the potential utility of angiogenesis inhibitors against 
cancer was identified. The term “anti‐angiogenesis” was proposed by Folkman's research group 
to refer to the inhibition of new vessel sprouts from penetrating into an early tumor implant [5].
Tumor endothelial cells lining the inner layer of blood vessels are the main targets of anti‐
angiogenic therapy. It is believed that new tumor vessels generally sprout from preexisting 
vasculature; accordingly, new tumor vessels are considered structurally and functionally nor‐
mal. However, recent studies have reported that tumor blood vessels differ morphologically 
and phenotypically from normal blood vessels [6]. A common feature in the architecture of 
the normal vasculature is a hierarchical and regular branching pattern. In contrast, tumor 
blood vessels are structurally distinct from normal blood vessels. Tumor endothelial cells, 
which are not comprised of regular monolayers, do not function as a normal barrier [7]. The 
pericytes form abnormally loose associations with these cells and extend cytoplasmic pro‐
cesses deep into the tumor tissue [8]. An inner layer of tumor blood vessels is composed of a 
specific phenotype of tumor‐associated blood endothelial cells. Furthermore, the tumor endo‐
thelial cells are heterogeneous according to the malignancy status of tumor [9].
3. Tumor‐specific angiogenesis
3.1. Cancer stem cells (CSCs) or tumor‐initiating cells
The American Association for Cancer Research (AACR) defined CSCs as subpopulations of 
cells within a tumor that possess the capacity for self‐renewal and generation of heteroge‐
neous lineages of cancer cells that constitute the tumor [10].
The cancer stem cell theory provides an attractive explanation for tumor proliferation and 
progression. According to this theory, tumors retain subsets of cells with functional hetero‐
geneity. However, the putative relationship between CSCs and tumor angiogenesis remains 
poorly understood [11].
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3.2. The origin of the endothelial cells in the tumor vasculature
The origin of endothelial cells in the tumor vasculature is not yet known [12]. Some stud‐
ies suggest that CSCs play an important role in tumor vascularization. The tumor stem cells 
defined as CSCs or tumor‐initiating cells are considered the source of tumor cells. Moreover, 
novel findings, which suggest that CSCs also give rise to endothelial cells in the tumor vas‐
culature, have been described in recent reports [2–4]. A proportion of endothelial cells that 
contribute to blood vessels in glioblastomas originate from the tumor itself, having differen‐
tiated from CSCs. A subset of endothelial cells that constitute tumor vessels carries genetic 
aberrations found in the tumor cells themselves. It has been shown that a glioblastoma cell 
population that could differentiate into endothelial cells and form blood vessels was enriched 
in cells expressing the tumor stem cell marker CD133.
3.3. The origin of pericytes in the tumor vasculature
Pericytes are mural cells that wrap around the endothelial cells of capillaries and venules. 
Vascular pericytes play important roles in supporting vascular structure and function. As 
communication between pericytes and endothelial cells has been demonstrated to occur, it 
is considered that pericytes may prove a novel target for tumor therapy [13]. A recent study 
has reported that glioblastoma stem cells give rise to vascular pericytes that support vessel 
function and tumor growth. These results suggest that CSCs from glioblastomas generate the 
majority of vascular pericytes [14].
4. Tumor angiogenesis via endothelial differentiation of human 
hepatoblastoma stem cells
We have investigated the relationship between tumor endothelial cells and CSCs in human 
hepatoblastoma, which is the most frequent type of malignant tumor that occurs in the pedi‐
atric liver.
4.1. Characteristics of human hepatoblastoma cells
4.1.1. CD133
CSCs exhibit specific cell membrane markers; CD133 is considered a stem‐like cell marker 
in various cancers [15–17]. In human hepatocellular carcinoma (HCC) and HCC cell lines, 
CD133 is expressed by only a minority of the tumor cell population. CD133+ cells exhibit the 
ability to self‐renew, produce differentiated progenies, and form new tumors [18, 19].
4.1.2. Cell culture
Human hepatoblastoma cell line (HuH‐6 clone 5, well‐differentiated type, JCRB0401) was 
procured from the Health Science Research Resources Bank (Osaka, Japan) and cultured in 
Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) and 
50 µg/mL gentamicin, according to a previously described protocol [20].
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4.1.3. SEM and TEM
For SEM observation, the samples were fixed in 0.1 M phosphate buffer (pH 7.2) containing 
2.5% glutaraldehyde for 1 h and subsequently fixed in 0.1 M phosphate buffer (pH 7.2) con‐
taining 1% OsO4 for 1 h, dehydrated in graded ethanol, and critical‐point air‐dried after treat‐ment with isoamyl acetate. The samples were sputter‐coated with OsO4 and observed under a SEM (Hitachi, S‐4800; Tokyo, Japan) [21].
For TEM, the cells were fixed in 0.1 M phosphate buffer (pH 7.2) containing 2.5% glutaralde‐
hyde for 1 h, followed by fixation in 0.1 M phosphate buffer (pH 7.2) containing 1% OsO4 for 
another hour. The specimens were dehydrated in graded ethanol, embedded in epoxy resin, 
cut into ultrathin sections, and stained with uranyl acetate and lead citrate. The stained ultra‐
thin sections were observed under a TEM (JEM‐1010; Tokyo, Japan) [21].
4.1.4. Distribution of CD133 in human hepatoblastoma cells
We investigated CD133 distribution in human hepatoblastoma cells. CD133 was mainly local‐
ized in membrane ruffles in the peripheral regions of the cell. Examination of the CD133‐
positive sites using SEM revealed that they coincided with filopodia and lamellipodia. TEM 
revealed that CD133 was preferentially concentrated in a complex structure formed by filopo‐
dia and lamellipodia [21] (Figure 1).
4.2. Isolation and identification of human hepatoblastoma stem cells
A key challenge in the study of CSCs is the development of reproducible and reliable methods 
for CSC isolation and identification. The side population (SP) assay identifies the fraction of 
cells that efflux Hoechst dye through ATP‐binding cassette (ABC) transporters. We identi‐
fied hepatoblastoma stem cells based on their ability to efflux Hoechst 33342 dye using flow 
cytometry, as described in Hayashi et al. [22]. A fraction of SP cells was analyzed by flow 
cytometry (FACS Vantage SE, BD, Tokyo, Japan) (Figure 2). SP cells were injected subcutane‐
ously into immunodeficient NOD/SCID mice (male, 4‐week‐old: Charles River Japan Inc.), 
and tumor growth was evaluated. All animal experiments were approved by the Institutional 
Animal Care and Use Committee of Saitama Medical University.
4.3. Sphere formation assay and three‐dimensional collagen gel culture system
Digested xenograft tumor fragments were cultured, and tumor sphere assay was carried out. 
The spheres were cultivated using three‐dimensional collagen gel culture methods, referring 
to the previous reports [23–25]. The spheres were fixed with 4% paraformaldehyde/phosphate 
buffer saline (PBS) and then embedded in Technovit 8100 (T8100, Heraeus Kulzer, Wehrheim, 
Germany) according to the manufacturer's instructions.
4.4. Immunohistochemical detection of CD133
The location of CD133 expression was examined in Technovit‐embedded sections (Figure 3). 
Some spheres were observed to form capillary‐like structures (Figure 4).
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Immunostaining for correlative observation by light microscopy and electron microscopy was 
performed, according to previously described methods [21], to detect the expression of CD133 
in these capillary‐like structures. The spheres were incubated with primary anti‐CD133 anti‐
body (Santa Cruz Biotechnology, CA). Alexa Fluor 488‐ and 1.4‐nm nanogold‐conjugated goat 
Figure 1. Immunohistochemical analyses of CD133 in hepatoblastoma cells by light microscopy, scanning electron 
microscopy (SEM), and transmission electron microscopy (TEM). (A) Intense immunolabeling of CD133 was observed 
at the peripheral regions of cells (arrow numbers 1, 2, 3, and 5) by light microscopy. Nanogold labeling was followed by 
gold enhancement for 20 min. Arrow number 4 indicated a negative site; scale bar: 50 µm. (B) SEM image of the sample 
shown in A; the peripheral region of cells (arrow numbers 1, 2, 3, and 5) coincided with the positive sites observed 
in A. (C) Higher magnification of SEM images of the positive sites shown in B; the positive sites were composed of 
a complex structure of filopodia and lamellipodia. (D) TEM analysis: CD133 was preferentially concentrated in the 
complex filopodial structure and at the leading edge of lamellipodia. The clustered particles form black spots; scale bar: 
5 µm. (Modified from Akita et al. [21]).
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anti‐rabbit IgG (Nanoprobes, Yaphank, NY, USA) were used as secondary antibodies. The 
nanogold signal was enhanced using GoldEnhance EM (Nanoprobes) for 20 min. The spheres 
were analyzed by light microscopy (Figure 5, inset). The spheres of interest were subjected to 
the gold‐enlargement procedure using GoldEnhance EM (Nanoprobes, Yaphank, NY, USA) 
to an appropriate size for TEM analysis, according to the manufacturer's instructions. Some 
spheres formed CD133‐positive capillary‐like structures. TEM imaging of these structures 
confirmed the presence of identifiable lumens (Figure 5, bottom).
Figure 3. Immunofluorescence of hepatoblastoma tumor sphere. Immunofluorescence of tumor sphere labeled with 
anti‐CD133 antibody (green); nuclei stained with DAPI (blue). The overlaid image is shown in the right panel (merge); 
scale bar: 40 µm.
Figure 2. Identification and characterization of side population (SP) cells from a hepatoblastoma cell line. The SP cells in 
hepatoblastoma cells were identified by flow cytometry using a Hoechst33342‐based staining procedure. (A) The SP cells 
displayed in plots show a tail‐like subpopulation close to the G0/G1 phase (on the left). Representative images of dot plot 
analysis by FACS demonstrating the presence of 2.45% SP cells. (B) The ABC transporter inhibitor verapamil effectively 
blocks the export of the Hoechst dye, thus leading to the disappearance of the SP subpopulation. SP cells were reduced 
to 1.02% upon treatment with verapamil.
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Figure 4. Tube formation assay of hepatoblastoma tumor sphere. Phase‐contrast microscopy shows a tubular structure 
sprouting (arrowheads) from hepatoblastoma tumor sphere (S) in a three‐dimensional collagen gel. Higher magnification 
of the inset indicated bottom; scale bar: 90 µm (inset), 40 µm (bottom).
Figure 5. Immunohistochemical detection of CD133 in capillary tubes. (Inset) Light microscopy showed that the capillary 
tube formed from the hepatoblastoma tumor sphere (S) in the collagen gel was positive for CD133 (arrowheads). 
Nanogold labeling was followed by gold enhancement for 20 min. (Bottom) Transmission electron microscopy (TEM) 
image of the sample shown in the inset; the cross section of this tube is shown. CD133 was detected in the capillary tube. 
The clustered particles form black spots (arrows); scale bar: 1 µm.
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5. Conclusions and perspectives
Tumor angiogenesis has been widely mentioned as a process that new blood vessels are devel‐
oped from preexisting host blood vessels surrounding the tumors. However, we propose a 
paradigm change. Our results suggest that CD133‐positive CSCs differentiate into tumor vas‐
cular endothelial cells and might be able to form tumor vessels.
Since Folkman hypothesized the notion of targeting tumor endothelial cells with anti‐
angiogenic therapy, numerous anti‐angiogenic drugs have been discovered. Previously, 
we reported that CD133‐positive capillary tubes were formed in vitro. Statins, which are 
widely used as cholesterol‐lowering agents, strongly inhibited the capillary tube forma‐
tion [26]. Statin diminished intraplaque angiogenesis [27] and reduced the growth and 
spread of many cancers [28, 29]. Khaidakov et al. suggested that statin had anti‐angiogenic 
effects [30]. We propose that the anti‐angiogenic effects of statins can be considered for the 
cancer therapy.
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